25 mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy

Berthelot, Jean‐Marie; Varin, Stéphane; Cormier, Grégoire; Tortellier, L.; Guillot, Pascale; Glémarec, Joëlle; Maugars, Yves

doi:10.1016/j.jbspin.2006.03.010

Cited by 16 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As one of the frequently used TNF-α inhibitors for AS patients, etanercept has been extensively investigated in its dosage adjustment strategy and corresponding efficacy. [ 29 – 32 ] Several studies suggest that tapering dose of etanercept is capable of keeping the remission after the standard treatment does in AS patients, but still a proportion of patients fail to maintain response to the tapering dose. [ 17 , 18 ] In the present study, the dose tapering group and the standard dose group were similar in decreasing the SPARCC score and the percentage of patients with BME in SIJ at each visit, whereas the percentage of patients achieving ASAS 40 response in dose tapering group was lower than that of standard dose group after 6-month etanercept treatment; these results might result from that (1) most diminishment of BME in SIJ occurred in the first 3-month while dose tapering of etanercept was moajoritliy applied at or after 3 months; meanwhile, standard dose group illuminated a numerically higher SPARCC score than dose tapering group; thus, SPARCC score and the percentage of patients with BME in SIJ were of no difference between dose tapering group and the standard dose group after treatment.…”

Section: Discussionmentioning

confidence: 99%

A quick decrease of bone marrow edema in sacroiliac joint could be served as a novel marker for dose tapering of etanercept in ankylosing spondylitis patients

2019

View full text Add to dashboard Cite

The purpose of this study was to investigate the correlation of bone marrow edema (BME) in sacroiliac joint (SIJ) with clinical characteristics and clinical response, and whether the quick decrease of BME could be served as a novel marker for dose tapering of etanercept in ankylosing spondylitis (AS) patients.Ninety active AS patients underwent etanercept treatment for 6 months were enrolled consecutively and classified into standard dose group (n = 37) and dose tapering group (n = 53). BME in SIJ and clinical response were assessed by SPARCC criteria and ASAS 40 response criteria, respectively. “Quick decrease of BME in SIJ” was defined as the decrease of SPARCC score≥50% from M0 to M1.BME in SIJ was positively correlated with pain VAS score, BASDAI score, CRP, IL-1β, IL-17, and TNF-α levels. ASAS 40 response rate at M6 was lower in dose tapering group than standard dose group, while higher in patients with a quick decrease of BME in SIJ than other patients. Besides, the ASAS 40 response rate in dose tapering group was similar to standard dose group in patients with a quick decrease of BME in SIJ but was lower than standard dose group in patients without a quick decrease of BME in SIJ at M6.A quick decrease of BME in SIJ predicts better treatment response to etanercept, and it might be served as a novel marker for dose tapering initiation of etanercept in AS patients.

show abstract

Section: Discussionmentioning

confidence: 99%

A quick decrease of bone marrow edema in sacroiliac joint could be served as a novel marker for dose tapering of etanercept in ankylosing spondylitis patients

2019

View full text Add to dashboard Cite

show abstract

“…The recommended dosage is 25 mg twice weekly or ETN50, with comparable clinical outcomes expected with either dose [1]. However, ETN exhibits unique pharmacokinetic and pharmacodynamic properties that may result in very similar benefits with ETN25 as compared with ETN50 in certain clinically controlled patients [7,14]. This data may be correlated with the considerably greater affinity of ETN for soluble TNF-a in comparison with anti-TNF-a antibodies [15].…”

Section: Discussionmentioning

confidence: 99%

Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients

Borrás-Blasco

Gracia-Pérez

Rosique-Robles

et al. 2013

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

“…However, in a Japanese clinical trial (TNR-001), no significant difference in efficacy was observed between groups administered etanercept at 10 mg 9 2/week and 25 mg 9 2/week [5]. A French study also found no difference in clinical efficacy between etanercept 25 mg once weekly and twice weekly [19]. The use of half doses of etanercept has the potential to prevent the destruction of articular cartilage.…”

Section: Discussionmentioning

confidence: 99%

Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab

Matsuno

2010

Mod Rheumatol

View full text Add to dashboard Cite

This study was carried out to determine the effectiveness of half-dose administration of etanercept in patients with rheumatoid arthritis (RA) who exhibited secondary loss of efficacy of infliximab. Seventeen patients were administered 25 mg of etanercept once weekly for at least 1 year after secondary loss of efficacy of infliximab. The mean duration of treatment with infliximab was 32.5 ± 1.3 months. The patient cohort consisted of 3 males and 14 females, with a mean age of 56.3 ± 11.4 years and mean weight of 57.2 ± 10.9 kg. The mean duration of RA was 16.2 ± 10.9 years. The mean Disease Activity Score 28 was decreased significantly, from 5.8 at the initiation of infliximab therapy to 3.6 at the end of observation. There were no withdrawals due to adverse reactions during the study period, although in 2 subjects the agent was changed to tocilizumab due to lack of effect, one after 18 months and the other after 36 months, and 1 subject withdrew after 18 months for financial reasons. A good response can be expected to a half dose of etanercept in patients with secondary loss of efficacy of infliximab. Reduction of the patient's cost burden also makes this a superior treatment.

show abstract

25 mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy

Cited by 16 publications

References 17 publications

A quick decrease of bone marrow edema in sacroiliac joint could be served as a novel marker for dose tapering of etanercept in ankylosing spondylitis patients

A quick decrease of bone marrow edema in sacroiliac joint could be served as a novel marker for dose tapering of etanercept in ankylosing spondylitis patients

Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients

Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab

Contact Info

Product

Resources

About